Article

Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trial

2022-11-22

Abstract excerpt

<h4>SUMMARY</h4> <h4>Background</h4> This COVID-19 pandemic has caused unprecedented morbidity, mortality, and global economic instability. Several approved vaccines demonstrated to be effective prevention against COVID-19. We aimed to evaluate the safety and immunogenicity of the PIKA-adjuvanted recombinant SARS-C0V-2 Spike (S) protein subunit vaccine in adults as a primary immunization and as a booster dose agai...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a4a983c1-c434-5c5a-ac96-c427d11120da
DOI: 10.1101/2022.11.20.22282565

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Safety, Tolerability, and Immunogenicity of PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults: Interim results of an open-label and randomised Phase 1 clinical trialDOI 10.1101/2022.11.20.22282565Read

Phase I study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-BSemantic proximity Read

Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS‐CoV‐2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo‐controlled trialSemantic proximity Read

Phase I Interim Results of a Phase I/II Study of the IgG-Fc Fusion COVID-19 Subunit Vaccine, AKS-452Semantic proximity Read

Long-Term Safety and Immunogenicity of an MF59-Adjuvanted Spike Glycoprotein-Clamp Vaccine for SARS-CoV-2 in Adults Aged 18–55 Years or ≥56 Years: 12-Month Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 1 TrialSemantic proximity Read

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineSemantic proximity Read

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled TrialSemantic proximity Read

The COVID-19 pandemic: viral variants and vaccine efficacySemantic proximity Read

Safety and immunogenicity of a recombinant DNA COVID-19 vaccine containing the coding regions of the spike and nucleocapsid proteins: Preliminary results from an open-label, phase 1 trial in healthy adults aged 19–55 yearsSemantic proximity Read

A Phase1 Results of a Non-Stabilized Spike-Encoding mRNA Vaccine in AdultsSemantic proximity Read

Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled StudySemantic proximity Read

First Report of a Phase 1 Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2Semantic proximity Read

Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blind, Randomised, Placebo-Controlled Phase 2 TrialSemantic proximity Read